Fibrobiologics Inc
FBLG0.616USD
-0.033-5.03%
시장 운영 시간 （ET）시세는 15분 지연됩니다
25.17M시가총액
손실P/E TTM
자세한 내용은 Fibrobiologics Inc 회사
FibroBiologics, Inc. is a cell therapy regenerative medicine company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The Company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat Multiple sclerosis (MS) and has completed the Phase I study. The Company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing.
회사 정보
종목 코드 FBLG
회사 이름Fibrobiologics Inc
상장일Jan 31, 2024
CEOMr. Pete O'Heeron
직원 수13
유형Ordinary Share
회계 연도 종료Jan 31
주소455 E. Medical Center Blvd
도시HOUSTON
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호77598
전화12816715150
웹사이트https://fibrobiologics.com/
종목 코드 FBLG
상장일Jan 31, 2024
CEOMr. Pete O'Heeron
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
+177.78%
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
7.50K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Mr. Matthew Link
Mr. Matthew Link
Independent Director
Independent Director
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
+177.78%
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
7.50K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Mon, Jul 28
마지막 업데이트: Mon, Jul 28
주주
주주 유형
주주
주주
비율
O'Heeron (Peter)
14.10%
Golden Knight Inc LP
5.10%
BlackRock Institutional Trust Company, N.A.
3.90%
The Vanguard Group, Inc.
3.39%
Geode Capital Management, L.L.C.
1.47%
Other
72.05%
주주
주주
비율
O'Heeron (Peter)
14.10%
Golden Knight Inc LP
5.10%
BlackRock Institutional Trust Company, N.A.
3.90%
The Vanguard Group, Inc.
3.39%
Geode Capital Management, L.L.C.
1.47%
Other
72.05%
주주 유형
주주
비율
Individual Investor
15.84%
Investment Advisor
11.61%
Corporation
5.58%
Investment Advisor/Hedge Fund
4.21%
Research Firm
0.60%
Hedge Fund
0.18%
Bank and Trust
0.07%
Venture Capital
0.05%
Pension Fund
0.03%
Other
61.83%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
123
14.61M
38.17%
+89.36K
2025Q1
124
14.64M
40.12%
+123.60K
2024Q4
115
14.16M
40.30%
-9.06K
2024Q3
108
15.43M
44.70%
+1.86M
2024Q2
83
13.39M
40.93%
+2.95M
2024Q1
29
10.41M
31.81%
+483.30K
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
O'Heeron (Peter)
5.91M
15.44%
--
--
Apr 21, 2025
Golden Knight Inc LP
2.13M
5.58%
+9.85K
+0.46%
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
1.63M
4.27%
-25.68K
-1.55%
Mar 31, 2025
The Vanguard Group, Inc.
1.42M
3.71%
+508.69K
+55.79%
Mar 31, 2025
Geode Capital Management, L.L.C.
614.64K
1.61%
+9.71K
+1.61%
Mar 31, 2025
State Street Global Advisors (US)
566.45K
1.48%
-8.07K
-1.40%
Mar 31, 2025
Cascade Financial Partners, LLC
260.08K
0.68%
-22.52K
-7.97%
Mar 31, 2025
Northern Trust Investments, Inc.
201.64K
0.53%
-13.77K
-6.39%
Mar 31, 2025
UBS Financial Services, Inc.
112.86K
0.29%
-15.33K
-11.96%
Mar 31, 2025
Optivise Advisory Services, LLC
110.10K
0.29%
--
--
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
비율0%
ProShares Hedge Replication ETF
비율0%
Global X Russell 2000 ETF
비율0%
ProShares UltraPro Russell2000
비율0%
Proshares Ultra Russell 2000
비율0%
Texas Capital Texas Small Cap Equity Index ETF
비율0%
iShares Russell 2000 ETF
비율0%
iShares Micro-Cap ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
